<DOC>
	<DOCNO>NCT00006240</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combine phenylbutyrate , dexamethasone , sargramostim treat patient refractory relapse acute myeloid leukemia .</brief_summary>
	<brief_title>Phenylbutyrate , Dexamethasone , Sargramostim Treating Patients With Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response ( complete hematologic remission induction ) phenylbutyrate , dexamethasone , sargramostim ( GM-CSF ) patient refractory relapse ( 8 ; 21 ) acute myeloid leukemia . - Determine correlation histone acetylation , differentiation , apoptosis bone marrow mononuclear cell response rate patient treat regimen . - Determine overall survival patient regimen . - Determine correlation histone acetylation , differentiation , apoptosis bone marrow mononuclear cell pharmacokinetics regimen patient . - Determine safety toxicity regimen patient . OUTLINE : This multicenter study . Patients receive phenylbutyrate IV continuously sargramostim ( GM-CSF ) subcutaneously day 1-7 15-21 . Patients also receive oral dexamethasone day 1-4 15-18 . Treatment continue every 28 day absence disease progression unacceptable toxicity complete hematologic remission induce . Patients stable disease end 1 course receive least 2 additional course . Patients follow twice week 3 month , monthly 1 year , every three month next 4 year , annually thereafter . PROJECTED ACCRUAL : A total 9-24 patient accrue study least 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ( 8 ; 21 ) acute myeloid leukemia ( AML ) Failed standard induction chemotherapy stem cell transplantation ( SCT ) OR Relapsed standard induction chemotherapy SCT OR Refused candidate SCT match allogeneic sibling bone marrow transplantation donor lymphocyte infusion OR Refused candidate autologous SCT bone marrow transplantation No CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 7 day Hematopoietic : Not specify Hepatic : AST ALT great 3 time upper limit normal ( ULN ) Bilirubin great 3 time ULN No hepatic disease would preclude study Renal : Creatinine great 2 mg/dL Creatinine clearance least 60 mL/min No renal disease would preclude study Cardiovascular : No cardiac disease would preclude study No New York Heart Association class III IV heart disease No myocardial infarction within past 8 week Other : No active infection except cystitis Not pregnant nursing No alter mental status seizure disorder No serious disease would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : At least 3 week since prior investigational antineoplastic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>